A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
Status:
Not yet recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
The aim on this study is to assess the safety and efficacy of the anti-VEGFR2 monoclonal
antibody olinvacimab and the capecitabine in patients with metastatic colorectal carcinoma
who failed two prior chemotherapies